Combination of Artificial Intelligence and Extended Reality, that provides users with an easier and quicker way to create, visualize, and explore the nuances of molecular structure in one solution by SoftServe R&D.
Watch the video
Identifying a molecular drug target
Researchers must understand the underlying mechanisms of the disease as clearly as possible.
Identifying the first lead compound
Find a compound that acts on the target in the desired way
Lead optimization
Starting with the first lead compound, chemists run tests, and iteratively refine a succession of a structurally related compound until they find the optimal active structure
Pre-clinical safety and efficacy trials
At this stage, investigations primarily focus on safety. Before human candidates are tested, a number of critical pre-clinical hurdles must be overcome
Human clinical trials
Human trials establish safety, tolerability, dosage, and efficacy
Regulatory approval and launch
Finally, documentation of experiments and results must be prepared
A typical drug design lifecycle
inevitably goes through several stages:
Start to finish, the process usually lasts 10 to 15 years
The cost of a conventional drug
is over $1B
and only one drug out of thousands of candidates ever reaches the patient
from ideation to final approval and commercial distribution
We have created a solution that challenges legacy paradigms allowing to speed up the delivery of effective results
solution
Efficient design and screening of novel compounds is a major challenge in drug and material design
SoftServe’s extended reality (XR) molecular explorer unites XR and artificial intelligence (AI) to provide users with an easy way to generate a new compound, visualize it, and examine its molecular structure.